In this presentation we will share our journey towards scaling our R-usage from our first submission, and the feedback we have received from authorities in doing so.

We will highlight our strategic direction and what role open-source will play for Novo Nordisk in future submissions.
Ari Siggaard Knoph | Ari Siggaard Knoph | Steffen Falgreen Larsen
Novo Nordisk | Novo Nordisk | Novo Nordisk
Our R-Based Submissions: A 1-year follow-up, Lessons Learned, and Future Strategies
In this presentation we will share our journey towards scaling our R-usage from our first submission, and the feedback we have received from authorities in doing so.  We will highlight our strategic direction and what role open-source will play for Novo Nordisk in future submissions.